Recurrent HCC followingTACE

Recurrent hepatocellular carcinoma (HCC) following transarterial chemoembolisation (TACE) is a significant clinical challenge. TACE is widely used as a treatment modality for HCC, particularly for patients with intermediate-stage disease or as an adjuvant therapy after curative resection to target residual microscopic disease. However, recurrence remains a common issue, and understanding the factors contributing to recurrence, as well as strategies for managing recurrent HCC, is essential for improving patient outcomes.

Factors Contributing to Recurrence Following TACE:

1. Tumour Biology: Aggressive tumour characteristics, such as poor differentiation, vascular invasion, or high alpha-fetoprotein (AFP) levels, are associated with a higher risk of recurrence.

2. Incomplete Tumour Necrosis: TACE relies on selective embolisation of tumour-feeding arteries, but incomplete necrosis of the tumour may leave residual viable cancer cells that can proliferate.

3. Micrometastases: Occult micrometastases that are not detectable at the time of initial treatment can lead to recurrence.

4. Liver Function: Patients with compromised liver function (e.g., cirrhosis) may have a higher risk of recurrence due to reduced ability to tolerate treatment and impaired immune surveillance.

5. TACE Technique: Variability in the technical execution of TACE, such as insufficient embolisation or suboptimal drug delivery, can contribute to recurrence.

Patterns of Recurrence:

Recurrent HCC after TACE can manifest as:

• Intrahepatic Recurrence: New tumour nodules within the liver, either near the original site or in different segments of the liver.
• Extrahepatic Metastasis: Spread to distant organs, such as lungs, bones, or lymph nodes, which is less common but associated with worse prognosis.

Management of Recurrent HCC Following TACE:

1. Repeat TACE:

• Patients with recurrent HCC confined to the liver may benefit from repeat TACE, provided liver function is preserved and the tumour burden remains manageable.
• The interval between TACE sessions and the patient's tolerance to treatment should be considered.

2. Systemic Therapy:

• Targeted therapies such as sorafenib, lenvatinib, or other tyrosine kinase inhibitors (TKIs) may be used for patients with advanced or recurrent HCC.
• Immunotherapy with immune checkpoint inhibitors (e.g., atezolizumab plus bevacizumab) has emerged as a promising option for recurrent HCC.

3. Surgical Resection:

• If the recurrence is localized and the patient is a suitable surgical candidate, re-resection may be considered.
• This option is typically reserved for patients with good liver function and limited tumour burden.

4. Liver Transplantation:

• In cases of recurrent HCC meeting Milan or UCSF criteria, liver transplantation may offer a curative option, particularly for patients with underlying cirrhosis.

5. Ablative Therapies:

• Techniques such as radiofrequency ablation (RFA) or microwave ablation (MWA) may be used for small, localized recurrent tumours.

6. Combination Approaches:

• Combining locoregional therapies (e.g., TACE plus RFA) or systemic therapies with TACE may enhance outcomes and reduce recurrence rates.

Prognostic Tools and Risk Stratification:

To guide management decisions, predictive models and tools, such as the online calculator mentioned in the context, can be used to estimate recurrence risk and tailor treatment strategies. These tools integrate tumour-related factors, surgical details, and patient characteristics to provide personalised recommendations.

Preventive Strategies:

1. Optimising TACE Protocols: Ensuring adequate embolisation and drug delivery during the initial TACE procedure can reduce the risk of recurrence.

2. Adjuvant Therapies: In high-risk patients, adjuvant therapies such as systemic agents or combination locoregional treatments may be considered to prevent recurrence.

3. Surveillance: Regular imaging and AFP monitoring post-TACE are critical for early detection and management of recurrence.

Conclusion:

Recurrent HCC following TACE is a complex issue influenced by tumour biology, treatment efficacy, and patient factors. Management requires a multidisciplinary approach, incorporating locoregional therapies, systemic treatments, and predictive tools to optimise outcomes. Advances in risk stratification and treatment modalities hold promise for reducing recurrence and improving survival in patients with HCC.